Greifswald - CHEPLAPHARM is expanding its portfolio by acquiring the marketing rights for Rivotril from Roche.

'We were able to complete this very important project as a successful start to the new year. Rivotril perfectly complements our portfolio of benzodiazepines marketed worldwide. We are proud to be able to build on the long-standing business relationship with Roche,' says Managing Director Sebastian F. Braun about the Takeover of the established brand among patients and prescribers.

Rivotril is a branded prescription drug that is used to treat epilepsy and panic disorder. This benzodiazepine with the active ingredient clonazepam is a well-established product that is marketed worldwide. Rivotril was introduced in 1973 and is currently approved in approximately 85 countries.

Contact:

Tel: +49 (0) 3834 3914-0

Fax: +49 (0) 3834 3914-119

Email: info (at)cheplapharm.com

(C) 2021 Electronic News Publishing, source ENP Newswire